Skip to main content

Table 7 Incremental cost-effectiveness ratio of PHiD-CV vs. PCV13 vaccination programs

From: Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan

  PCV13 (A) PHiD-CV (B) Difference (B−A)
Total discounted costs (NTD) 1 392 017 676 1 383 217 323 -8 800 353
Total discounted QALYs gained 1 799 828 1 799 849 21
Incremental cost-effectiveness ratio Dominant (cost saving)
  1. PCV13 13-valent pneumococcal conjugate vaccine, PHiD-CV 10-valent pneumococcal polysaccharide and NTHi protein D conjugate vaccine, NTD new Taiwan dollar, QALY quality-adjusted life year
\